---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-082579"
form_type: "8-K"
ticker: "LIMN"
cik: "0001971387"
company_name: "Liminatus Pharma, Inc."
filed_at: "2025-08-25T23:59:59+00:00"
generated_at: "2026-05-17T10:22:38.589290+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Liminatus Pharma receives Nasdaq delinquency notice for late Q2 10-Q filing; has 60 days to submit compliance plan

## Summary
- Nasdaq notified Liminatus on Aug 22, 2025 of non-compliance with Listing Rule 5250(c)(1) due to delayed Form 10-Q for period ended June 30, 2025.
- Company has 60 days, until Oct 21, 2025, to submit a plan to regain compliance; Nasdaq may grant extension to Feb 16, 2026 if plan accepted.
- Common stock (LIMN) continues to trade on Nasdaq; no immediate delisting effect.
- Liminatus is a pre-clinical stage biopharma developing immune-modulating cancer therapies.

## SEC filing metadata
- accession: 0001104659-25-082579
- form_type: 8-K
- ticker: LIMN
- cik: 0001971387
- company_name: Liminatus Pharma, Inc.
- filed_at: 2025-08-25T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971387/000110465925082579/0001104659-25-082579-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971387/000110465925082579/tm2524293d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-082579
- JSON: https://secwatch.observer/filing/0001104659-25-082579.json
- Plain text: https://secwatch.observer/filing/0001104659-25-082579.txt

## Key facts
- Listing & Compliance Notices
  Liminatus Pharma, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: late filing
  - Rules: 5250(c)(1)
  source text: August 22, 2025, Liminatus Pharma, Inc. (the “Company”) received a notice from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that the Company was no longer in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delay in filing its Quarterly Report on Form 10-Q for the period ended June 30, 2025 (the “Form 10-Q”). The deficiency letter has no immediate effect on the listing of the Company’s common stock, and its common stock will continue to trade on Nasdaq under the symbol “LIMN” at this time. Under the Nasdaq rules, the Company has 60 calendar da
  evidence_url: https://www.sec.gov/Archives/edgar/data/1971387/000110465925082579/0001104659-25-082579-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.